[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?
Actas Dermo-Sifiliográficas · 2024
DOI: 10.1016/j.ad.2023.10.036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von D Moreno-Ramírez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain. Electronic add…. Hauptthemen laut MEDLINE: Mutation, Proto-Oncogene Proteins B-raf, Immunotherapy, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Systemic treatment with immunotherapy or targeted therapy can significantly improve survival in patients with advanced (metastatic or high-risk) melanoma. Fifty percent of patients with melanoma have a BRAF mutation. Decisions on optimal sequencing of systemic treatments should take into account drug- and tumor-related factors and patient characteristics. Although the combination of ipilimumab and nivolumab is associated with the best survival outcomes, it is associated with significant toxicity. Targeted therapy may be a more favorable option in certain clinical situations. We review the literature on immunotherapy and targeted therapy in melanoma and present an algorithm for guiding decision-making on their use as first-line systemic treatments for advanced BRAF-mutated melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain. Electronic address: dmoreno@e.derma-org.
- Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain.
Zitieren
APA
Moreno-Ramírez, D., Fernández-Orland, A., & Ferrándiz, L. (2024). [Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.10.036
Vancouver
Moreno-Ramírez D, Fernández-Orland A, Ferrándiz L. [Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.10.036
BibTeX
@article{MorenoRamrez2024,
author = {Moreno-Ramírez, D and Fernández-Orland, A and Ferrándiz, L},
title = {[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?},
journal = {Actas Dermo-Sifiliográficas},
year = {2024},
doi = {10.1016/j.ad.2023.10.036}
}
EUVIMED